BofA lowered the firm’s price target on Fractyl Health (GUTS) to $2 from $5 and keeps a Buy rating on the shares after the company provided new, six-month randomized controlled data of its Revita procedure in weight maintenance post-discontinuation of a GLP1 therapy. The “data were not perfect,” but the firm thinks the pivotal results should benefit from a much larger sample size and optimization of trial execution, says the analyst, who lowered the firm’s sales forecast pending clarity on the profile strength based on additional data.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health downgraded to Equal Weight from Overweight at Morgan Stanley
- Fractyl Health Advances Revita for Post-GLP-1 Weight Maintenance
- Fractyl Health announces results from trial evaluating Revita
- Biotech Alert: Searches spiking for these stocks today
- Fractyl Health price target lowered to $8 from $10 at Morgan Stanley